While orforglipron succeeded in a Phase 3 trial, its weight loss effects were more modest than investors and analysts ...

Eli Lilly said on Thursday that its experimental GLP-1 pill helped patients lose 12.4% of their body weight in a late-stage ...

Weight-loss drugs are expected to pull in more than $150 billion in industry-wide revenue by the early 2030s, thanks to the ...

In an 18-month clinical trial of the experimental GLP-1 pill orforglipron, about 60 percent of people lost at least 10 ...

Eli Lilly will seek regulatory approval for its next-generation weight-loss pill by year-end, based on data that suggests it ...

The company said it planned to seek Food and Drug Administration approval for the drug, orforglipron, before the end of the ...

At Shifa hospital in the Gaza Strip, nothing is sterilized, so Dr. Jamal Salha and other surgeons wash their instruments in ...

Recently released results from a clinical trial on orforglipron show that the oral medication can cause impressive weight ...

Lilly executives have touted the once-daily pill, known as orforglipron, as a cheaper alternative to recently-popular obesity injections like its Zepbound offering or Novo’s Wegovy. Both of the ...

Novo Nordisk shares surged more than 11% in premarket trading Thursday after Eli Lilly’s data on its oral obesity drug ...

A new Ozempic-like pill has led to “significant” weight-loss in a major trial, paving the way for a new era of obesity ...